Reappraisal of the use of procarbazine in the treatment of lymphomas and brain tumors
نویسندگان
چکیده
Procarbazine HCl is a 'nonclassical' oral alkylating anticancer agent that was first synthesized in the late 1950s. It has been used in the treatment of many cancers, but its main use is in the treatment of Hodgkin's lymphoma and brain tumors and, to a lesser extent, Non-Hodgkin's lymphoma and primary central nervous system lymphoma. Procarbazine is a prodrug that undergoes metabolic transformation into active intermediates that are thought to inhibit DNA, RNA, and protein synthesis. Early use of procarbazine in combination with mechlorethamine, vincristine, and prednisone (MOPP) was effective in the treatment of advanced Hodgkin's lymphoma, but late toxic effects such as secondary cancer and infertility led to its replacement by other regimens. However, its recent reintroduction in the dose-intensified BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has yielded very promising findings. Procarbazine alone, or more commonly combined in the PCV (procarbazine, lomustine [CCNU], and vincristine) regimen, is also effective in treating gliomas comprising astrocytomas, glioblastomas, and oligodendrogliomas. The most common side effects of procarbazine are gastrointestinal disturbances, myelosuppression, and central nervous system effects. In conclusion, the use of procarbazine in combination with other drugs means that it remains a major anticancer drug in the management of Hodgkin's lymphoma and gliomas.
منابع مشابه
Comparison of brain SPECT with 99mTc-MIBI and CT-scan in discriminating of radiation necrosis and brain tumor recurrence [Persian]
Introduction: 99mTc-MIBI has been proposed for use as an imaging agent for various tumors, including breast cancer, lung cancer, lymphomas, melanomas and brain neoplastic lesions. Brain tumors are very common and radiotherapy being major part of treatment following surgery. After radiotherapy, deteriorating clinical status can be due to either radiation necrosis or recurrent tumor. Comput...
متن کاملA Practical Guide to Differential Diagnosis of Small B Cell Lymphomas
Correct diagnosis and classification of lymphoid neoplasms depends on the integration of morphologic, immunophenotypic and molecular genetic features. The mature small B cell lymphomas despite their overlapping histomorphologies, have different clinical behavior and treatment. In this review, differentia...
متن کاملP128: Relationship of Childhood Brain Tumors and Hair Dye Usage During Pregnancy
Brain tumors, which is one of the destructive forms of human being’s cancers, are the second most common children’s cancers. Brain tumors may have an inherited (small percent), acquired reasons due to environmental factors. Nowadays advances in cosmetic industry have increased our ability in the field of youth and beauty. Hair dye products are such innovations. Recent studies showed...
متن کاملA Two-Dimensional Convolutional Neural Network for Brain Tumor Detection From MRI
Aims: Cancerous brain tumors are among the most dangerous diseases that lower the quality of life of people for many years. Their detection in the early stages paves the way for the proper treatment. The present study aimed to present a two-dimensional Convolutional Neural Network (CNN) for detecting brain tumors under Magnetic Resonance Imaging (MRI) using the deep learning method. Methods & ...
متن کاملPRIMARY MALIGNANT TUMORS OF THE SMALL INTESTINE: ANALYSIS OF 156 IRANIAN PATIENTS
156 Iranian patients with primary malignant tumors of the small intestine were reviewed. Malignant lymphoma was the most common tumor type, comprising 128 patients (82%), followed by adenocarcinoma (22 patients, 14.1 %), leiomyosarcoma (4 patients, 2.56%) and carcinoid tumor (2 patients, 1.28%). Lymphomas and adenocarcinomas were primarily located in the duodenum or jejunum, whereas leiomy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Therapeutics and Clinical Risk Management
دوره 3 شماره
صفحات -
تاریخ انتشار 2007